Access Course

 

Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

 

This activity is intended for oncologists, pulmonologists, and pathologists.

 

The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

 

 

 

 

 

 

Approximate Time to Complete: 15 minutes

 

Credit Available: Dec. 18, 2018- Dec. 18, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors in the management of SCLC
  • Have increased knowledge regarding how emerging data are advancing the treatment paradigm in SCLC
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.25
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.25